Subjective complaints may cause patients to stop treatment after switching to a biosimilar

A biosimilar is a biological medicine that shows no clinically meaningful differences with another already approved biological medicine (the 'reference medicine'). A new study in Arthritis & Rheumatology found that one-quarter of patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who switched from reference infliximab to biosimilar infliximab (called CT-P13) stopped taking CT-P13 during six months follow-up, mainly due to subjective health complaints.

The substantial discontinuation rate of CT-P13 after open-label transitioning might be explained by the awareness of clinicians and patients of the transition. This awareness might induce negative expectations about transitioning to a biosimilar, resulting in negative symptoms during treatment (nocebo effect) and/or incorrect causal attributions.

"As a result, communication between clinicians and patients seems to be the determining factor of the success of transitioning to a biosimilar in daily practice", said lead author Dr. Lieke Tweehuysen, of Sint Maartenskliniek, in the Netherlands.

Explore further

Biosimilar switching not suitable for all patients

More information: Lieke Tweehuysen et al, Subjective Complaints as Main Reason for Biosimilar Discontinuation after Open Label Transitioning from Originator to Biosimilar Infliximab, Arthritis & Rheumatology (2017). DOI: 10.1002/art.40324
Provided by Wiley
Citation: Subjective complaints may cause patients to stop treatment after switching to a biosimilar (2017, October 18) retrieved 11 August 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments